Biopharmaceutical company Humanigen Inc (HGEN) announced on Sunday that it has signed a partnership with EVERSANA for introducing the investigational treatment lenzilumab to hospitalized and hypoxic COVID-19 patients upon receipt of the US FDA's Emergency Use Authorization and BLA.

According to Humanigen, lenzilumab is a proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody that is designed to prevent and treat cytokine storm, a leading cause of COVID-19 death.

Data showed that up to 89% of hospitalized patients with COVID-19 are hypoxic and at risk of this immune hyper-response, which can trigger acute respiratory distress syndrome in severe cases of COVID-19, stated the companies.

In anticipation of an EUA for the use of lenzilumab in hospitalized COVID-19 patients, Humanigen has immediate access to EVERSANA's fully integrated services including, but not limited to, marketing, market access, medical education, health economics and outcomes research, medical information, compliance and medical science liaison teams, with each service optimized by data and predictive analytics.